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Abstract
 
Transforming growth factor (TGF)-
 
 
 
1, a potent immunoregulatory molecule, was found to
control the life and death decisions of T lymphocytes. Both thymic and peripheral T cell apop-
 
tosis was increased in mice lacking TGF-
 
 
 
1 (TGF-
 
 
 
1
 
 
 
/
 
 
 
) compared with wild-type litter-
mates. Engagement of the T cell receptor enhanced this aberrant T cell apoptosis, as did signal-
ing through either the death receptor Fas or the tumor necrosis factor 
 
 
 
 receptor in peripheral
T cells. Strikingly, TGF-
 
 
 
 was localized within the mitochondria of normal T cells, and the
absence of TGF-
 
 
 
1 resulted in disruption of mitochondrial membrane potential (
 
  
 
m
 
), which
marks the point of no return in a cell condemned to die. This TGF-
 
 
 
–dependent regulation of
viability appears dissociable from the TGF-
 
 
 
1 membrane receptor–Smad3 signaling pathway,
but associated with a mitochondrial antiapoptotic protein Bcl–XL. Thus, TGF-
 
 
 
1 may protect
T cells at multiple sites in the death pathway, particularly by maintaining the essential integrity
of mitochondria. These findings may have broad implications not only for T cell selection and
death in immune responses and in the generation of tolerance, but also for defining the mech-
anisms of programmed cell death in general.
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Introduction
 
Null mutation of the murine TGF-
 
 
 
1 gene (TGF-
 
 
 
1
 
 
 
/
 
 
 
)
results in multiorgan lymphocyte and macrophage infiltra-
tion, massive inflammation, and untimely death of the ani-
mals within 3–4 wk (1, 2), consistent with the critical role
of TGF-
 
 
 
1 in regulating immune and inflammatory re-
sponses (3–6). Paradoxically, however, attempts to induce
peripheral null T cell proliferative responses by triggering
the TCR with anti-CD3 monoclonal antibody or with mi-
togens in vitro were unsuccessful (7, 8). Moreover, these
mice have smaller thymuses and spleens than those of age-
matched TGF-
 
 
 
1
 
 
 
/
 
 
 
 littermates (1, 7), indicative of T cell
depletion, perhaps through enhanced apoptosis.
The apoptotic process can be divided into at least three
functionally overlapping phases: initiation, effector, and
degradation (9–12). In T cells, the initiation phase includes
ligation of death receptors, particularly Fas (13–17) and
TNF-
 
 
 
 receptors (18). However, normal T cells (19, 20)
are typically resistant to apoptosis induced with the coun-
 
terreceptor Fas ligand (FasL),
 
*
 
 despite expression of Fas an-
tigen. Only extensive antigenic stimulation in the presence
of IL-2 (generation of T cell blasts) is reportedly able to
sensitize peripheral T cells to FasL and TNF-
 
 
 
, rendering
them susceptible to activation-induced cell death (AICD).
 
During the subsequent effector phase, death receptor–
mediated signals can be translated into a regular pattern of
metabolic reactions and the “decision to die” is taken. In
this chain of events, changes in mitochondrial membrane
potential (
 
  
 
m
 
) appear irreversibly lethal for the cell and
can lead to release of death factors (9–12). How normal
 
  
 
m 
 
is maintained is not fully understood, although antiap-
 
optotic
 
 
 
Bcl-2 family members reportedly play a part in pre-
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*
 
Abbreviations used in this paper: 
 
7-AAD, 7-amino-actinomycin D; 
 
  
 
m
 
,
 
mitochondrial membrane potential; AICD, activation-induced cell
death; DiOC
 
6
 
, 3,3
 
 
 
-dihexyloxacarbocyanine iodide; DP, double positive;
ER, endoplasmic reticulum; FasL, Fas ligand; GAPDH, glyceraldehyde
3-phosphate dehydrogenase gene; PALS, periarteriolar lymphatic sheath;
TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-
biotin nick end-labeling. 
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venting both 
 
  
 
m
 
 dissipation and the release of cyto-
chrome c and/or apoptosis-inducing factor (21–23).
 
Although TGF-
 
 
 
1 has been implicated in influencing
AICD in T cells, the mechanism remains unclear (24–26).
Whereas one report demonstrated that TGF-
 
 
 
1 inhibited
FasL expression without affecting Fas-mediated death sig-
 
naling, another indicated that TGF-
 
 
 
1 did reduce Fas-
 
mediated apoptosis. These controversial findings are based on
the effects of exogenous TGF-
 
 
 
1 on normal T cells or hy-
bridoma cell lines, which produce their own TGF-
 
 
 
 (8,
27–29). Another intriguing observation was the identifica-
tion of TGF-
 
 
 
 within mitochondria (30), but its function in
this context is totally unknown. We investigated how TGF-
 
 
 
1 influences apoptotic processes by examining the death
 
behavior of T cells deficient in TGF-
 
 
 
1 (TGF-
 
 
 
1
 
 
 
/
 
 
 
) or
lacking an intact TGF-
 
 
 
 signaling pathway (Smad3
 
 
 
/
 
 
 
).
 
Materials and Methods
 
Mice.
 
TGF-
 
 
 
1
 
 
 
/
 
 
 
 (C57BL/6
 
 
 
Sv129; reference 2) and age-
matched TGF-
 
 
 
1
 
 
 
/
 
  
 
mice were housed in a specific pathogen-
free rodent facility at the National Institute of Dental and Cranio-
facial Research. DO11.10 OVA peptide TCR transgenic mice
were purchased from The Jackson Laboratory.
 
In Situ Detection of Apoptotic Cells in Tissues with Terminal Deox-
ynucleotidyl Transferase (TdT)-mediated dUTP-biotin Nick End-label-
 
ing Method.
 
Thymuses and spleens from TGF-
 
 
 
1
 
 
 
/
 
 
 
 and
age-matched TGF-
 
 
 
1
 
 
 
/
 
 
 
 mice were fixed with 10% buffered
formalin and 5–6-
 
 
 
 paraffin sections placed on slides. DNA frag-
 
mentation was detected with a terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP-biotin nick end-labeling (TUNEL) kit
(ApopTag@Plus Peroxidase, S7101-kit; Intergen Co.) after 1 h
treatment with proteinase K and counterstained with 0.5% (wt/
vol) methyl green for photomicroscopy with a Leica microscope.
 
7-Amino-Actinomycin D Staining of Apoptotic Cells.
 
Staining of
apoptotic cells with 7-amino-actinomycin D (7-AAD; Calbio-
chem) was performed as described previously (8, 31). In brief,
cells were first stained with FITC–anti-CD8 and PE–anti-CD4
mAbs (Caltag), washed, and incubated with 7-AAD (20 
 
 
 
g/ml)
in PBS containing 2% FBS and 0.1% sodium azide at 4
 
 
 
C for 20
min protected from light. Multiparameter data analysis was per-
 
formed with Lysis II software. Cell subsets were gated, and
7-AAD staining on fluorescence channel-3 (FL-3) versus forward
scatter channels was displayed.
 
Anti-CD3 mAb Treatment In Vitro and In Vivo.
 
In vitro, freshly
isolated thymocytes or spleen cells were stimulated with soluble
anti-CD3 mAb (5 
 
 
 
g/ml 145-2C11; BD PharMingen) in com-
plete DMEM for 12–16 h. In vivo, TGF-
 
 
 
1
 
 
 
/
 
 
 
 and TGF-
 
 
 
1
 
 
 
/
 
 
 
mice were injected intraperitoneal with anti-CD3 antibody (50
 
 
 
g per mouse) in 50 
 
 
 
l PBS or PBS only. After 6–16 h, tissues
were processed and stained with TUNEL or isolated cells were
stained with 7-AAD.
 
Assessment of mRNA for Apoptosis-related Molecules.
 
Total RNA
was isolated from freshly isolated thymocytes or spleen cells using
a modification of guanidinium isothiocyanate method (RNeasy
kit; QIAGEN) for RNase Protection assay (32). A multiple tem-
plate mAPO-3 or mAPO-2 set (BD PharMingen) was used, and
radiolabeled probes were generated using [
 
33
 
P]dUTP (New En-
gland Biolabs, Inc.). Individual mRNAs were normalized as the
ratio of mRNA for death receptors (FasL, Fas, TNF–related
apoptosis-inducing ligand, and TNF-
 
 
 
 p55) to the constitutively
expressed L32 or glyceraldehyde 3-phosphate dehydrogenase
gene (GAPDH).
 
Induction of T Cell Apoptosis In Vitro.
 
Spleen cells were cultured
 
in complete DMEM with recombinant human TNF-
 
 
 
 (50 ng/ml;
R&D Systems), recombinant murine TNF-
 
 
 
 (40 ng/ml; R&D
Systems), or anti-Fas antibody (1 
 
 
 
g/ml Jo2; BD PharMingen)
for 16 or 56 h. Some spleen cells were cultured with anti-CD3
and anti-Fas (Jo2) antibodies for 16–24 h. Cells were then stained
with FITC–anti-CD8 and PE–anti-CD4 together with 7-AAD
for evaluation of apoptosis. Number of viable cells (7-AAD
 
 
 
) in
parallel untreated cultures was considered as 100%. In some ex-
periments, peripheral T cells were isolated from spleens as de-
scribed previously (8). Purified T cells were incubated with cross-
linked anti-CD3 (2 
 
 
 
g/ml) or plus anti-CD28 (5 
 
 
 
g/ml; BD
PharMingen) antibodies by goat anti–hamster IgG (20 
 
 
 
g/ml)
 
(Pierce Chemical Co.) for 16 h. Cells were then stained with
 
7-AAD for detection of cell death. CD8
 
 
 
CD44
 
 
 
/low
 
 T cells (naive)
 
were purified (
 
 
 
99%) from spleen cells of TGF-
 
 
 
1 null (6–10-
d-old, pooled from five mice) or age-matched wild-type (
 
n
 
   
 
5)
mice by flow cytometry using FITC-conjugated anti-CD8 and
PE-conjugated anti-CD44 (antibodies were depleted of sodium
azide by dialysis in PBS overnight) on a FACStar
 
plus™
 
 Cell Sorter
(Becton Dickinson).
In some experiments (see Fig. 9), lymph node cells (10–11-
 
d-old mice, 
 
n
 
   
 
5) were pooled and stimulated with plate-coated
 
anti-CD3 (10 
 
 
 
g/ml) in the presence of soluble anti-CD28 (5
 
 
 
g/ml) antibodies or medium overnight. Some cells were har-
vested and adjusted for equal number of live cells in each treat-
ment (30   106) for RNA and protein extraction. For Western
blot analysis, an anti-Bcl–XL antibody (BD PharMingen) was
used as described previously (33). Bcl–XL mRNA analysis was
performed by RPA by using the mAPO-2 set template. Some
cells were washed three times and then irradiated (1,200 rad)
with a  -irradiator (Gammacell 1000; Atomic Energy of Canada)
and cultured in complete DMEM for an additional 6–24 h. For
viability, cells were assessed by Trypan blue exclusion or by 7-AAD
staining.
Flow Cytometry Analysis. Cell staining for surface markers was
performed as described previously (8). In brief, cells were incu-
bated with FITC–anti-CD8, PE–anti-CD4, and biotin-conju-
gated anti-Fas (Jo2), anti-FasL, anti-CD44, anti-CD45RB, anti-
CD69, or anti-CD62L antibodies (from BD PharMingen or
Caltag), followed by streptavidin-tricolor (Caltag). Multiparame-
ter data analysis was performed with Lysis II software.
Isolation of the Mitochondria and Cytosol from Cells. Isolation of the
mitochondria from cells was done according to the published
protocol (22). In brief, T cell pellets were washed with ice-cold
PBS and resuspended in buffer A (20 mM Hepes-KOH, pH 7.5,
10 mM KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM so-
dium EGTA, 1 mM dithiothreitol, and 0.1 mM phenylmethysul-
fonyl fluoride) containing 250 mM sucrose (thymocytes: 100  
106 cells in 500  l; peripheral T cells: 15–30   106 cells in 200–
250  l). The cells were homogenized with 10 strokes of a Teflon
homogenizer, and the homogenates were centrifuged twice at
750 g for 10 min at 4 C. The pellets were discarded and the su-
pernatants were centrifuged at 10,000 g for 15 min at 4 C. The
resulting mitochondrial-enriched pellets were resuspended in the
original volumes of buffer A and frozen at  80 C. The superna-
tants of the 10,000 g spin were frozen at –80 C. Some superna-
tants were further centrifuged at 100,000 g for 1 h at 4 C, and the
resulting supernatants were frozen at  80 C. An aliquot of mito-
chondrial sample was fixed with 2.5% glutaraldehyde for exami-
nation by an electron microscope (Zeiss EMIO microscope). For441 Chen et al.
analysis of TGF-  by ELISA, samples were treated with 1N HCl
(1  l per 50  l supernatant) for 15 min at room temperature and
neutralized with an equal amount of 1N NaOH. Samples were
diluted (1:5) with the sample dilution buffer included in the
TGF- 1 ELISA kit (Promega).
Western Blot Analysis. Aliquots of mitochondria and cytosol
preparations (20  g protein) were subjected to 12.5% SDS-PAGE
and transferred to a nitrocellulose filter (GIBCO BRL). The nitro-
cellulose membrane was blocked for 1 h with 5% instant skim milk
powder in TBS. The filter was probed with an antibody to LAP-
TGF- 1 (0.2  g/ml anti-rhLAP; R&D Systems), washed, and in-
cubated with horseradish peroxidase linked with Protein A as rec-
ommended by the manufacturer (Amersham Pharmacia Biotech).
Finally, the washed blots were exposed to an enhanced chemilumi-
nescence detection system (Amersham Pharmacia Biotech) and re-
corded on an autoradiograph (Kodak X-Omat film).
Immunostaining of TGF-  in T Cells. Splenic CD4  and CD8 
T cells were incubated with mitochondrion-selective dye Mito-
Tracker® Red CMXRos (50 nM; Molecular Probes) in com-
plete DMEM at 37 C for 40 min. After washing with warm PBS,
cells were fixed with Cytofix/Cytoperm® (Cytofix/Cytoperm
Plus™ kit; BD PharMingen) at 4 C for 20 min. 106 cells were
washed with Perm/WashTM buffer (BD PharMingen) and incu-
bated with chicken anti–TGF-  (10–20  g, AB-101-NA; R&D
Systems) or with goat anti–human LAP (TGF- 1) (50  g AB-
246-NA; R&D Systems) at 4 C for 30 min. Cells were washed
twice with Perm/Wash™ buffer and stained with cyanine (Cy2)-
conjugated F(ab)2 donkey anti–chicken IgY or FITC-conjugated
F(ab)2 donkey anti–goat IgG antibodies (Jackson ImmunoRe-
search Laboratories) at 4 C for 30 min. For negative staining con-
trols, MitoTracker® Red-stained cells were incubated with sec-
ondary Cy2- or FITC-conjugated antibodies as above. After
two washes, cells were resuspended in staining buffer (PBS-
BSA[0.5%]–Az[0.1%]) and subjected to fluorescence microscopy.
Detection of   m and Reactive Oxygen Species in T Cells. To detect
  m, cells were first stained with PE–anti-CD4 or PE–anti-CD8
antibodies, washed, and resuspended in complete DMEM con-
taining 25 nM dye 3,3 -dihexyloxacarbocyanine iodide (DiOC6;
Molecular Probes) for 40 min at 37 C as described previously
(34). For determination of intracellular reactive oxygen species,
cells were incubated with dihydroethidium (2.5  M) in complete
DMEM at 37 C for 40 min (34). For dual labeling, FITC-conju-
gated anti-CD4 or -CD8 staining was performed at 4 C, before
incubation with the dye. CD4  T cells or CD8  T cells were
gated and the histograms of DiOC6 are displayed on FL-1 or of
dihydroethidium on FL-2.
Electron Microscopy. Thymus tissues were fixed in a solution
containing 0.5% glutaraldehyde and 4% paraformaldehyde, stained
with 1% osmium tetroxide, dehydrated with ethanol, and embed-
ded in Epon/Araldite resin. Thin sections were cut, stained with
3% aqueous uranyl acetate and Reynolds lead citrate, and ob-
served in a Zeiss EM10-A transmission electron microscope.
Immunoelectronmicroscopy. Spleen cells were fixed with 4%
paraformaldehyde in PBS containing 0.1% glutaraldehyde for 30
min and cell pellets were stabilized in 2% agar in PBS. Pellets
were rinsed with PBS, followed by a graded ethanol series (50,
70, 95%). Pellets were then infiltrated with LR White (hard
grade, Ted Pella, Inc.) at 1:1 (95% ethanol:LR White), then two
changes of pure LR White and left in pure LR White overnight
at room temperature. After one change of pure LR White, the
cell pellets were placed into BEEM capsules, filled with LR
White, and the capsules sealed with parafilm and the capsule top.
Polymerization took place at 70 C for 16 h.
Thin sections were cut on an RMC MT-7 and placed on
formvar/carbon-coated 200 nickel grids. All immunolabeling was
done in a microwell staining mold (Ted Pella, Inc.) placed in a
humid chamber. Grids were placed on a drop of blocking buffer
containing BSA, Tween 20, cold water fish gelatin, and serum
from either normal goat or rabbit. Grids were immunolabeled
with 80  g of goat anti-LAP (TGF- 1; R&D Systems). Negative
controls were exposed to blocking buffer in place of the primary
antibody. Secondary antibodies were either rabbit anti–goat con-
jugated to a 10-nm gold particle in a 1:20 dilution with blocking
buffer. Grids were subsequently stained with 2% aqueous uranyl
acetate and Reynold’s lead citrate and examined using a Zeiss
10A transmission electron microscope operating at 60 kV.
Results
Increased Thymic Apoptosis in Mice Lacking TGF- 1. To de-
fine a role for TGF-  in apoptosis of T cells, we first exam-
ined thymocyte apoptosis in situ with the TUNEL method
(35, 36). In the normal TGF- 1 /  thymus, apoptotic cells
were scattered throughout the cortex as reported (36) and
also found in the thymic medulla, although with less fre-
quency (Fig. 1 A). In the TGF- 1 /  mice, a significantly
enhanced number of TUNEL-positive cells was observed
in both thymic cortex and medulla (Fig. 1 B). To quantify
the apoptotic cells, freshly isolated thymocytes were stained
with DNA dye 7-AAD, which discriminates live cells from
apoptotic and/or dead cells, in combination with antibodies
which recognize CD4  and CD8  T lymphocytes for flow
cytometry (31). In the total population, 2–4% of the TGF-
 1 /  thymocytes were apoptotic, more than double the
number in the TGF- 1 /  thymocytes (0.5–1.5%) (31, 36).
Increased apoptosis occurred in both CD4 CD8  double
positive (DP) and CD4 CD8  or CD4 CD8  single posi-
tive thymocytes (Fig. 1 F), but not in the CD4 CD8  dou-
ble negative (DN) thymocytes (data not shown).
Since TGF- 1 /  mice develop extensive tissue inflam-
mation between 2–4 wk, one may argue that increased
apoptosis occurs secondary to the inflammatory response.
However, a significant decrease in the total number of thy-
mocytes was observed before symptoms appeared (9–10-
d-old TGF- 1 /  mean: 149   106 thymocytes; TGF- 1 / 
278   106, n   2). Subsequent peripheral inflammation
may further increase thymocyte apoptosis ( 3-wk-old
TGF- 1 /  mean: 70   106, n   4; TGF- 1 / : 345  
106, n   2). To determine whether inflammation and/or
cytokines contributed to this early apoptotic phenotype,
thymocytes and spleen cells from asymptomatic null (6–10 d
old) and wild-type mice were evaluated for cytokine
mRNA levels. No significant increase in cytokine mRNA
(TNF-  or IFN- ) was found in freshly isolated thy-
mocytes or spleen cells. Furthermore, sera from neither
asymptomatic null nor age-matched wild-type mice had de-
tectable levels of TNF- , IFN- , IL-2, or IL-4 (data not
shown). Importantly, we examined the thymuses of fetal
mice as early as gestation day 18, namely at a stage when
thymocyte positive selection is just beginning and cell
death is very limited (36, 37). While TUNEL staining was442 TGF- 1 Controls T Cell Apoptosis
seldom seen in TGF- 1 /  thymuses (Fig. 1 C, TUNEL 
cells: 0–1 per high power field, original magnification:
40 ), increased apoptosis was already evident in fetal
TGF- 1 /  thymocytes (Fig. 1 D, TUNEL  cells: 6–20
per high power field, original magnification: 40 ). The re-
sults indicate a requirement in vivo for TGF- 1 in T cell
development through its ability to influence thymocyte
apoptosis, which appears to occur after thymocytes acquire
expression of CD4 and CD8. Moreover, this is the first ev-
idence that the absence of TGF- 1 exerts an effect on the
immune system in utero and is associated with aberrant im-
munological development.
Peripheral T Cell Apoptosis in TGF- 1 Null Mice. Be-
cause the absence of TGF- 1 has such a profound influence
on thymocyte survival, we next examined the impact of
TGF- 1 deficiency on peripheral T cells. Although by flow
cytometry, reduction of both CD4  and CD8  T cell num-
bers occurred in the spleens of young, asymptomatic TGF-
 1 /  mice (Fig. 1 G), the decrease was more significant in
CD8  T cells, skewing the CD4/CD8 ratio toward CD4
(4.5 in TGF- 1 null versus 2.5 in wild-type, 6 d). With in-
creasing age, the percentage of both CD4  and CD8  T
cells increased (Fig. 1 G, 10 d), but the disproportionate re-
duction in CD8  T cells remained. A similar profile was
also evident in lymph node cells (data not shown). Increased
apoptotic cells (7-AAD ) were evident in CD4  and partic-
ularly CD8  TGF- 1 /  T cells (Fig. 1 H). Although this
enhanced apoptosis became more pronounced as the TGF-
 1 /  mice developed symptomatic inflammation ( 3 wk
old, data not shown), increased peripheral T cell apoptosis
was clearly evident within 6–7 d of birth (Fig. 1, G and H),
before evidence of inflammation or enhanced cytokine ex-
pression. This increased sensitivity to apoptosis appears to be
a basic feature of TGF- 1 gene–deleted T cells.
TGF- 1 Controls Activation-induced T Cell Death. The im-
pact of TCR stimulation on T cell death in the absence of
Figure 1. Apoptotic cells in thymus and
spleen of TGF- 1 /   and TGF- 1 / 
mice. (A–E) In situ detection of apoptotic
cells in thymus sections with a modified
TUNEL method. Original magnification:
40 . (A) TGF- 1 /  thymus (11 d). (B)
TGF- 1 /  thymus (11 d). (C) Fetal gesta-
tion day 18 TGF- 1 /  thymus: stained
cells are seldom seen. (D) Fetal gestation day
18 TGF- 1 /  thymus: stained cells are
clearly evident. (E) TGF- 1 /  thymus
stained in the absence of TdT (negative
control), no stained cells. (F) Detection of
apoptotic cells by staining with 7-AAD in
thymocyte subsets. The values are mean  
SD of three experiments (six mice per
group, 11–16 d old). TGF- 1 /  (open);
TGF- 1 / (solid). (G–H) Enhanced apop-
tosis in peripheral TGF- 1 /  T cells. (G)
Profiles of surface CD4  versus CD8  stain-
ing of spleen T cells. (6, 10 d). (H) 7-AAD 
cells within CD4  or CD8  splenocyte T
cell subsets (7 d).443 Chen et al.
TGF- 1 was even more impressive. Activation of thy-
mocytes with anti-CD3 antibody exacerbated thymocyte
apoptosis, affecting CD4 CD8  DP cells more than
CD4 CD8  and CD4 CD8  single positive cells (Fig. 2).
Apoptotic DP thymocytes also downregulated CD4 and
CD8 surface expression (31, 38) concomitant with positive
staining for 7-AAD (Fig. 2 A), yielding more CD4  low
CD8  low DP thymocytes in TGF- 1 /  mice (41%)
than in TGF- 1 /  thymocytes (21%, Fig. 2 A, R2). Un-
precedented, however, was the response to intraperitoneal
injection of anti-CD3 mAb (50  g per mouse). Although
anti-CD3 injection into 11–12-d-old wild-type mice trig-
gered apoptosis of thymocytes, primarily in the cortex (Fig.
2 D) as reported (36, 39), and total thymocyte numbers de-
creased two to threefold compared with a mock PBS injec-
tion (PBS mean: 300   106, n   2; mAb CD3 mean: 156  
106, n   2), TGF- 1 null thymuses manifested enor-
mous numbers of TUNEL-stained cells within hours after
anti-CD3 antibody injection (Fig. 2 E). Moreover, large
aggregates of apoptotic cells, particularly in the cortex,
were apparent and often localized within distended macro-
phages, and surprisingly, TUNEL-stained cells were also
seen in thymic medulla (Fig. 2 E). Total thymocyte num-
bers in anti-CD3 mAb–treated TGF- 1 /  mice dropped
precipitously by 10-30-fold (PBS mean: 120   106, n   2;
mAb CD3 mean: 5   106, n   2). By flow cytometry,
substantially more CD4  lowCD8  low (24 vs. 7%) and
7-AAD  thymocytes were present in anti-CD3–treated null
mice compared with wild-type (data not shown). Thus, the
absence of TGF- 1 has a profound influence on the sensi-
tivity of thymocytes to TCR-mediated apoptosis, particu-
larly in the CD4  CD8  DP population, to influence their
negative selection.
Extending these studies to the peripheral lymphoid tis-
Figure 2. Detection of apoptotic cells in-
duced by anti-CD3 mAb in vitro and in
vivo. (A) Anti-CD3 mAb (16 h) induced
more apoptosis of CD4 CD8  DP thy-
mocytes in TGF- 1 /  than TGF- 1 / 
mice in vitro. CD4  hi CD8  hi (R1) and
CD4 /lowCD8  low (R2) DP thymocytes
were gated and the percentages are dis-
played in lower right corner. The histo-
grams of 7-AAD staining of R1 (open) and
R2 (filled) on FL-3 are overlayed in right
panel. (B) Anti-CD3–induced cell death in
TGF- 1 /  peripheral T cells in vitro. Via-
ble CD8  T cells (2   105) purified from
spleens of mice (9–10 d old) were stimulated
with the indicated antibodies cross-linked
with goat anti–hamster IgG antibody for 16 h.
Cells were then stained with 7-AAD for
detection of cell death (7-AAD : apoptotic;
7-AAD : viable). Spleen cells (five mice per
group) were pooled before CD8  T cell
isolation. (C) Increased apoptosis of CD8 
CD44 /low naive null T cells in vitro. Flow
cytometry purified live CD8 CD44 /low
peripheral T cells (105) were cultured
with the indicated antibodies (2  g/ml
anti-CD3; 5  g/ml anti-CD28; 1  g/ml
anti-Fas) and cross-linked with goat anti–
hamster IgG antibody (20  g/ml) for 16 h.
Cells were then stained with 7-AAD for
apoptosis detection. Numbers shown in the
figure represent the percentage of viable
cells (7-AAD ). (D–G) In situ detection of
apoptotic cells with TUNEL staining in tis-
sues 16 h after anti-CD3 mAb injection. (D)
TGF- 1 /  thymus; (E) TGF- 1 /  thy-
mus; (F) TGF- 1 /  spleen; (G) TGF- 1 / 
spleen. Cor, cortex; GC, germinal center;
Med, medulla.444 TGF- 1 Controls T Cell Apoptosis
sues, purified peripheral viable CD8  T cells (Fig. 2 B) and
CD4  T cells (data not shown) were stimulated with anti-
CD3 alone or together with anti-CD28 antibodies for
16 h. TGF- 1 null T cells exhibited enhanced spontaneous
cell death and the anti-CD3 stimulation further increased
this aberrant T cell apoptosis. Even more dramatically,
cross-linking of CD3 together with CD28 promoted ex-
tensive cell death in the purified CD8  TGF- 1 null pop-
ulation (Fig. 2 B). Although many freshly isolated periph-
eral null T cells expressed CD44hi (Fig. 3), suggestive of
activation, when CD8 CD44 /low (naive) null T cells were
purified and cultured in media (Fig. 2 C), they still mani-
fested profound spontaneous T cell death (57% survival,
7AAD ) compared with wild-type (85% survival). Treat-
ment with anti-CD3 or anti-CD3 plus CD28 antibodies
further exacerbated this abnormal naive null cell death (13
and 21% survival, respectively), whereas the same treat-
ment only minimally induced or failed to drive cell death
in the wild-type T cells (80 and 86%, respectively). More-
over, unstimulated TGF- 1 null T cells failed to release
detectable TNF- , IFN- , or IL-2. Anti-CD3 treatment
in vitro induced these cytokines, but the levels in the null
T cell cultures were typically lower than the wild-type
controls. Inclusion of neutralizing anti–TNF-  and/or
anti–IFN-  antibodies did not reverse null T cell death
(data not shown). Thus, by multiple criteria, prior activa-
tion and secondary cytokines do not appear to represent
the mechanism underlying null T cell apoptosis.
In vivo injection of anti-CD3 mAb induced only sparse
TUNEL-positive cells in wild-type spleen, mainly in the T
Figure 3. Upregulation of apoptosis-
related molecules in TGF- 1 /  peripheral
T cells (10–11-d-old mice). (A) mRNA de-
tection in spleens (pooled cells from five
mice per group) by RPA. The experiment
represents one of five experiments. (B) The
ratio of mRNA of death receptors was nor-
malized as a ratio to the constitutively ex-
pressed GAPDH. Data presented are mean  
SEM (n   5). (C and D) Increased sur-
face expression of Fas and FasL on periph-
eral TGF- 1 /  CD4  and CD8  T cells.
CD4  or CD8  T cells are gated and the
profiles of CD4 or CD8 versus Fas (C) or
FasL (D) are shown. (E) Histograms of
CD44, CD45RB, CD69, and CD62L of
CD4  and CD8  T cells in lymph nodes
are shown on FL-3.445 Chen et al.
cell–dependent regions (periarteriolar lymphatic sheaths
[PALSs]), but seldom in the B cell–rich germinal centers
(Fig. 2 F). In marked contrast, in mice with the TGF- 1
gene deletion, massive apoptosis occurred throughout all
regions of the spleen. The larger and more intense aggre-
gates of TUNEL-positive cell clusters were found scattered
not only throughout the PALSs, but also in the B cell–
dependent germinal centers (Fig. 2 G). Within hours after
anti-CD3 mAb injection, tricolor fluorescence revealed a
significant increase in apoptotic (7-AAD ) cells in both
CD4  and CD8  T cell populations (data not shown).
This dramatic effect on activated T cell death, whether in
vitro or in vivo, occurs independent of mouse age (7–20 d
old) and underscores a requirement for TGF- 1 in the
maintenance of activated lymphoid cell viability.
TGF- 1 Regulates Fas-mediated Death Signaling in Periph-
eral, but Not Thymic T Cells. Whether the ligand-death
receptor pair, FasL–Fas, was involved in the dysregulated
apoptosis in T cells of TGF- 1 /  mice was assessed by
multiple parameters. By RNase Protection assay (32), com-
parison of thymocytes from null and wild-type mice, with
or without anti-CD3 mAb stimulation, revealed no signifi-
cant differences in transcripts of the multiple death-related
molecules including FasL and Fas (data not shown), despite
the remarkable increase in numbers of TGF- 1 /  apop-
totic cells. Additionally, by flow cytometry, both wild-type
and null thymocytes expressed nondiscriminating levels of
Fas antigen on their surface (data not shown).
In contrast to the thymocytes, the TGF- 1 /  spleen
cells exhibited clearly increased levels of both Fas and FasL
mRNA compared with their TGF- 1 /  counterparts
(Fig. 3, A and B). Consistent with the mRNA, surface ex-
pression of Fas (Fig. 3 C) and FasL (Fig. 3 D) was signifi-
cantly elevated in both CD4  and CD8  T cells, perhaps
reflecting an activated state (40) in the absence of TGF- 1.
Paradoxically, peripheral CD4  and CD8  T cells, despite
their upregulation of FasL and Fas, expressed a unique hy-
brid phenotype, including CD44 , CD62Llow, CD69 ,
and CD45RBhi in symptom-free 10-d-old mice (Fig. 3 E).
With the spontaneous development of inflammation and
autoimmune-like lesions ( 3 wk), FasL–Fas expression on
peripheral T cells further increased, along with upregula-
tion of CD69 and CD25 (data not shown). Increased
FasL–Fas expression appears to be a phenotypic character-
istic of TGF- 1 /  peripheral T cells, which may be aug-
mented by secondary lymphocyte activation, pointing to
an involvement of TGF- 1 in the regulated expression of
FasL–Fas.
When we examined whether the absence of TGF- 1 in-
fluenced the Fas-mediated death signaling pathway, we
found that anti–mouse Fas monoclonal antibody (1  g/ml
Jo2), in the absence of the protein synthesis inhibitor cyclo-
heximide (41), triggered minimal apoptosis of TGF- 1 / 
CD4  CD8  DP thymocytes (10–20% increase) and only
modestly enhanced apoptosis in CD4  CD8  DP null thy-
mocytes (20–30% increase). In peripheral T cells, however,
differences in anti-Fas–induced death were more clearly
evident. Fas ligation with mAb Jo2 markedly induced
apoptosis of both CD4  and CD8  peripheral TGF- 1 / 
T cells (40–60%), without affecting viability of wild-type
spleen cells (Fig. 4 A). Since TGF- 1 /  T cells expressed
more Fas than TGF- 1 /  T cells (Fig. 3), one might rea-
sonably consider that the killing induced by anti-Fas anti-
body was solely due to the upregulated expression of Fas.
Surprisingly, however, when we stimulated TGF- 1 /  T
cells with anti-CD3 mAb overnight to upregulate equiva-
lent Fas expression (Fig. 4 B), mAb Jo2 still induced only
marginal apoptosis of CD4  T cells (15%), and failed to en-
gage specific cell death of wild-type CD8  T cells (Fig. 4
C). This specific Fas-induced apoptosis in null T cells was
apparently not mediated by secondary cytokines in the cul-
tures, since no detectable levels of IL-2, IFN- , or TNF- 
were observed. Addition of anti–TNF-  and/or anti–IFN- 
Figure 4. Enhanced sensitivity to Fas and TNFR2-mediated cell death
in TGF- 1 /  peripheral T cells. (A) Anti-Fas antibody (Jo2)-induced
apoptosis of both CD4  and CD8  T cells. Mouse TNF-  specifically
killed CD8 , but not CD4 , T cells in TGF- 1 /  spleens. Data are ex-
pressed as percentages of viable cells compared with control (cells in me-
dium alone) after 16 h culture (mean   SD; n   4 experiments). Typi-
cally, the background viability of cells cultured with complete DMEM
only (untreated cells) for 16 h is: TGF- 1 / : CD4  T cells 7-AAD ,
76.1%; 7-AAD , 22%; CD8  T cells 7-AAD , 60%; 7-AAD , 36.9%;
TGF- 1 /  CD4  T cells 7-AAD , 42.8%; 7-AAD , 56%; CD8  T
cells 7-AAD , 42.6%; 7-AAD , 55%. *P   0.05 compared with me-
dium-treated null cells. (B) Fas expression on splenic T cells after anti-
CD3 mAb (5  g/ml) stimulation overnight. (C) Failure of anti-Fas mAb
to induce apoptosis of TGF- 1 /  peripheral T cells expressing Fas anti-
gen. Percentages of viable cells within CD4  or CD8  T cells from
TGF- 1 /  (open) or TGF- 1 /  (solid) are displayed. Data are repre-
sentative of three experiments (five mice per group).446 TGF- 1 Controls T Cell Apoptosis
failed to rescue and/or prevent anti-Fas induced TGF-
 1 /  T cell death (data not shown). Importantly, when
flow cytometry sorted CD8 CD44 /low naive T cells were
exposed to anti-Fas antibody for 16 h, only TGF- 1 null,
but not wild-type, T cells were specifically killed by Fas-
mediated signaling (Fig. 2 C). While these observations are
consistent with the evidence that normal murine T cells are
typically resistant to anti-Fas antibody–induced apoptosis
(19), TGF- 1 /  T cells, on the other hand, are exquis-
itely sensitive to this route of death.
TGF- 1 Controls TNF-  Receptor 2(p75)-mediated Apop-
tosis in Peripheral CD8 , but Not CD4  T Cells. In addi-
tion to Fas-mediated apoptosis, T cell death can also be or-
chestrated through TNFR. Murine TNF-  binds to
TNFR2(p75), which is constitutively expressed on murine
peripheral T cells (42) and signals by a pathway distinct
from TNFR1(p55)-driven apoptosis of nonlymphoid cells
(43, 44) to cause death of mature CD8  T cell blasts after
48 or more h in culture (18). As a receptor discriminating
tool, human TNF-  binds exclusively to mouse TNFR1
(44, 45). In normal wild-type peripheral T cells, neither
murine nor human TNF- –induced specific apoptosis after
16 h in culture (Fig. 4 A). A striking difference occurred
when TGF- 1 null spleen cells were exposed to murine,
but not human TNF- , which drove rapid and significant
TNFR2-dependent apoptosis of CD8  (20–40%), but not
CD4  T cells (Fig. 4 A). After longer intervals (by 56 h),
 60% of TGF- 1 /  CD8  T cells were specifically killed
by murine TNF- , whereas CD4  T cells were spared,
implicating a CD8 -specific mechanism of TGF- –medi-
ated protection from TNFR2-mediated loss of life.
Exogenous TGF- 1 Failed to Rescue or Prevent Dysregulated
TGF- 1 null T Cell Death. To dissect the mechanism(s)
whereby TGF- 1 controls T cell life and death decisions,
we added exogenous TGF- 1 to the cells in an attempt to
restore TGF- 1 signaling pathways regulating viability.
TGF- 1 null mice express normal TGF-  receptors (un-
published data), yet exogenous TGF- 1 (2 ng/ml) added
to the cell cultures failed to rescue or prevent either sponta-
neous or death receptor-induced apoptosis in null CD4 
and CD8  T cells (Fig. 5 A). In fact, addition of TGF- 1
slightly enhanced null T cell apoptosis, whereas it did not
affect cell death in parallel 16 h wild-type T cell cultures
(Fig. 5 A). The bioactivity of exogenous TGF- 1 was ver-
ified by its profound suppression of antigen-specific prolif-
eration in OVA peptide TCR transgenic (DO11.10) T
cells: OVA (100  g/ml) 18, 212   2761 cpm TdR3H in-
corporation; OVA plus TGF- 1 (2 ng/ml) 1,538   519.
The failure to reverse aberrant apoptosis behavior in
TGF- 1 null T cells with exogenous TGF- 1, consistent
with our failure to rescue null mice from lethality with
TGF- , prompted exploration of whether traditional
TGF-  signaling pathways were involved in the control of
cell death. In this regard, ligand binding to TGF-  recep-
tors induces a signaling cascade which involves intracellular
Smads (46, 47). Due to the disruption of downstream sig-
naling from the receptor, mutation of the Smad3 gene
(Smad3 / ) manifests in uninhibited spontaneous T cell ac-
tivation. These Smad3 null T cells, when activated by anti-
CD3 antibody, were insensitive to the inhibitory effects of
TGF-  (47), even though TGF-  production in the mice
was intact. Analysis of death and depletion of the Smad3 / 
Figure 5. (A) Failure of exogenous TGF- 1 to prevent
and/or rescue T cell death in TGF- 1 /  mice. Spleen
cells were cultured with anti-Fas mAb (1  g/ml) or me-
dium in the absence of presence of recombinant human
TGF- 1 (2 ng/ml; R&D Systems) for 16 h. Profiles of
7-AAD  cells on FL3 versus cell sizes on forward scatter
channels are displayed. The percentages are presented as
7-AAD  cells within the CD4  or CD8  T cell subsets.
(B) Smad3 /  T cells show normal apoptosis. (B) Profiles
of CD4 versus CD8 surface staining in freshly isolated
spleen cells (n   2 per pooled group; 4 wk old).447 Chen et al.
T cells revealed that in marked contrast to TGF- 1 /  T
cells, neither CD4  nor CD8  T cell populations were re-
duced in Smad3 /  spleens (Fig. 5 B). By 7-AAD staining,
freshly isolated Smad3 /  CD4  T cells had little or no in-
crease in apoptotic cells (14%) compared with wild-type
(11%), whereas no difference in apoptosis was observed in
CD8  T cells (Smad3 / , 5.0%; wild-type, 5.5%). The ab-
solute numbers of splenic CD4  and CD8  T cells were
not reduced in Smad3 /  mice compared with the wild-
types. In fact, the total numbers of spleen T cells, particu-
larly CD8  T cells, increased in Smad3 /  mice, which
may reflect lack of TGF-  inhibitory signals (Smad3 / 
CD4 , 18   2.6   106; CD8 , 12   2.1   106, n   5;
wild-type CD4 , 11   0.2   106; CD8 , 5.8   0.1   106,
n   6). The lack of difference in apoptosis was apparent
even though the majority of the T cells also expressed
CD62Llow (47), more like memory cells. Culture of the
Smad3 /  T cells for 16 h revealed a similar rate of sponta-
neous death between the null and control cells. Anti-Fas
failed to induce specific CD4  or CD8  T cell apoptosis
(data not shown), which was quite distinct from the TGF-
 1 /  T cells (Figs. 2 and 4). In addition, Smad3 null mice
had normal development of thymocytes (47). Thus, the en-
hanced apoptosis evident in TGF- 1 /  T cells appeared
not to be a function of the TGF- 1 receptor–Smad3 signal
transduction pathway, suggesting an alternative, perhaps in-
tracellular site for TGF- 1–mediated control of apoptosis.
TGF- 1–dependent   m. Previous reports had demon-
strated an intracellular site for TGF- . Because TGF-  was
localized within the mitochondria of rat liver and myocar-
dial cells (30), we investigated this possibility in T cells. Af-
ter isolating the mitochondria and cytosol from wild-type
T cells, we compared the levels of TGF-  within the mito-
chondria-enriched and the mitochondria-depleted cytosol.
By Western blot analysis, higher levels of TGF-  were de-
tected in the mitochondrial preparations than in the cytosol
(Fig. 6 A). This was TGF- 1 specific, because the same
Western blot analysis showed no band with the mitochon-
drial fraction derived from TGF- 1 null cells (Fig. 6 A). By
ELISA, a three to fivefold higher level of total TGF-  was
found within the mitochondrial-enriched preparation than
in the cytosol of wild-type peripheral T cells, particularly in
the CD8  population (Fig. 6 B). The purity of the mito-
chondrial preparations was assessed by electron microscopy,
Figure 6. Localization of TGF-  in the mitochondria of
wild-type T cells. (A) Western blot analysis of TGF- 1 in
mitochondria and cytosol. Mitochondria and cytosol prepa-
rations were isolated from pooled spleen cells (S) or thy-
mocytes (T) in wild-type ( / ) and TGF- 1 null /  mice
(three to five mice per group). 20  g of protein was loaded
into each lane and probed with anti-LAP (TGF- 1) anti-
body. (B) Total TGF-  from the mitochondrial and cytosol
preparations of peripheral CD4  T cells (1–2   106 cells),
CD8  T cells (1–2   106 cells) is shown as mean   SD of
duplicate ELISA measurements. Cyto, cytosol; Mito, mito-
chondrial preparations. (C) Immunostaining for TGF- 1.
Spleen T cells were stained with MitoTracker® Red for mi-
tochondria (red) and goat anti-LAP (TGF- 1) followed by
FITC-conjugated F(ab)2 donkey anti–goat IgG antibody
(green). Colocalization of TGF-  and mitochondria is rep-
resented as yellow. (a) Green fluorescence of anti-LAP
(TGF- 1) in T cells, showing a punctate staining pattern in
the cytoplasm around the nucleus. (b) Red fluorescence of
mitochondria stained by MitoTracker® Red. (c) Overlay of
a and b to demonstrate colocalization of TGF- 1(LAP) in
the mitochondria represented by yellow. A representative
cell is shown. (d–f) A nonspecific control for anti–TGF- 1
staining in which the primary anti-LAP(TGF- 1) antibody
was omitted. No green fluorescence was seen (d), but mito-
chondria stained with MitoTracker® Red (e). No yellow
color was observed in the overlay of d and e (f). This exper-
iment was repeated at least five times with similar results.
The profiles of TGF- 1 and mitochondrion staining in
both CD4  and CD8  T cells were similar.448 TGF- 1 Controls T Cell Apoptosis
but potential contamination by endoplasmic reticulum
(ER) that contains TGF-  could not be completely ex-
cluded. Although an ER-specific enzyme like glucose-6
phosphatase (G-6-P) can be used to detect ER contamina-
tion in some cells such as liver, G-6-P does not appear to
be detectable in ER of mouse lymphocytes (data not
shown) and no other ER-specific enzyme has been re-
ported in lymphocytes. Consequently, we directly exam-
ined intact lymphocyte mitochondria for TGF- . We first
stained peripheral T cells with anti-LAP (TGF- 1) or anti–
TGF-  (data not shown) antibodies together with a mito-
chondria-tracking dye (Fig. 6 C). As evident in Fig. 6 C,
the anti-LAP stained the peripheral cytoplasm in a punctate
pattern. MitoTracker® was observed in a similar orientation
and the overlays revealed a colocalization (yellow) pattern
of the two stains. To further document this association
between TGF-  and the mitochondria, we performed im-
munogold labeling of spleen T cells with anti-LAP (TGF-
 1) antibody (Fig. 7). Gold grains are localized over mito-
chondria (Fig. 7, B–D, arrowheads), whereas ER and
nucleus show little or no labeling in these freshly isolated
spleen cells. This anti-LAP (TGF- 1) immunogold label-
ing was specific for TGF- 1, since omission of the primary
antibody resulted in no labeling (Fig. 7 A). By multiple ap-
proaches, the data are consistent with TGF- 1 localization
in T cell mitochondria and indicate that TGF-  in this in-
tracellular compartment might bypass membrane TGF- 
receptors to influence T cell apoptosis.
Since mitochondria function as intracellular integrators
of discrete proapoptotic stimuli and intact membrane po-
tential (  m) is indispensable for normal mitochondrial
function (9–11, 48), the effect of TGF- 1 deletion on   m
in T cells was monitored. In concert with their higher
rate of apoptosis, both TGF- 1 /  thymocytes (data not
shown) and peripheral T cells exhibited markedly de-
creased   m as determined by dye DiOC6 (34) which ac-
cumulates in intact mitochondria (Fig. 8 A, Fresh). Signifi-
cantly increased numbers of TGF- 1 /  T cells had
reduced   m (DiOC6
low) compared with the wild-type T
cells after 16 h in culture (Fig. 8 A, Med). Promotion of
death by anti-Fas antibody Jo2 further dampened their   m
(increase in DiOC6
low cells), but the wild-type T cells were
resistant to changes in   m (Fig. 8 A) and to Fas execution
(Fig. 4). Parallel with the apoptotic profile, murine TNF- 
reduced the   m in peripheral TGF- 1 /  CD8  (data not
shown), but not CD4  T cells (Fig. 8 A). Consistent with
the failure to rescue the cells from death, exogenous TGF-
 1 (2 ng/ml) also failed to prevent either spontaneous or
death receptor-induced loss of   m. Moreover, the ab-
sence of Smad3 did not appear to influence   m (data not
shown). These data again favor a nontraditional receptor-
dependent and/or intracellular role for TGF- 1 in main-
taining the integrity of   m.
Changes of Mitochondrial Morphology in TGF- 1 /  T
Cells. Consistent with the reduced   m in TGF- 1–defi-
cient T cells, we observed altered mitochondrial structural
integrity in the cells lacking intracellular TGF- 1. Ultra-
structural examination of mitochondrial structure revealed
aberrancies as early as gestation day 18 in fetal thymus,
when thymocyte positive selection was just beginning and
cell death was undetectable in normal mice (Fig. 1 C; refer-
ences 36 and 37), but discernible in the fetal null thymus
(Fig. 1 D, and data not shown). Null thymocytes with ab-
normal mitochondria were frequently detected even before
nuclear morphological changes indicative of apoptosis
emerged (Fig. 8, B and C), whereas mitochondrial archi-
tecture was protected in the TGF- 1 wild-type mice.
Failure of Bcl–XL Upregulation in TGF- 1 /  T Cells.
Since Bcl-2 family members influence apoptotic events and
are integral membrane proteins associated with the outer
membrane of mitochondria (22, 23), and since TGF- 1
was also demonstrated in mitochondria (30) (Figs. 6 and 7),
we next explored potential functional consequences of de-
letion of TGF- 1 on Bcl-2 family molecules. We focused
on inducible Bcl–XL, which inhibits translocation of death
factors from the mitochondria to prevent apoptosis in T
cells (33, 49). Prestimulation of normal T cells with anti-
CD3 plus anti-CD28 upregulates Bcl–XL (Fig. 9 A) to pre-
vent subsequent apoptosis induced by nonspecific  -irradi-
ation (33). In marked contrast, in TGF- 1 null T cells,
anti-CD3 and anti-CD28 failed to significantly increase ei-
ther Bcl–XL mRNA or protein (Fig. 9 B) and thus, many
fewer cells were rescued from the secondary apoptosis in-
Figure 7. Immunogold labeling for TGF-  in mouse spleen cells. (A)
Control gold labeling in the absence of the primary antibody. No immu-
noreaction was observed over the mitochondria (M). (B) Specific labeling
of TGF- 1 in mitochondria (M) with anti-LAP (TGF- 1). Gold grains
are localized predominantly over mitochondria (arrowheads). ER and nu-
cleus show little or no labeling. (C and D) Representative immunogold
labeling for LAP (TGF- 1) in the mitochondria from additional cells.
Cell fixation and preparation as described in Materials and Methods.
Original magnification: 106,000 .449 Chen et al.
duced by  -irradiation (Fig. 9 C). It appears that the pres-
ence of TGF- 1 is associated with intact   m and expres-
sion of Bcl–XL to control T cell viability.
Discussion
Our findings have uncovered an apparent essential role
for TGF- 1 in central thymocyte development and selec-
tion, and in the maintenance of peripheral lymphocyte ho-
meostasis, by virtue of its ability to control their survival.
The unexpected increase in apoptosis in TGF- 1 /  thy-
mocytes indicates a previously unrecognized link between
TGF- 1 and T cell development within the thymus. Al-
though the secondary inflammation may exacerbate the
dysregulated thymocyte apoptosis, significant increases in
apoptosis and decreased total thymocyte number occur be-
fore overt signs of inflammation and immunopathology.
Furthermore, our in situ apoptosis study with TUNEL
(Fig. 1 D) in day 18 fetal thymuses strongly supports TGF-
 1 as an inherent factor in controlling thymocyte death
and selection, since at this stage, normal thymocyte death
is undetectable (36, 37) (Fig. 1 C). Despite extensive anal-
yses, there has to date, been no evidence that inflam-
mation occurs before birth, or even perinatally, in the
TGF- 1 null mice, in large part due to the maternal-fetal
transfer of TGF- 1 (50). Thus, even in the presence of mater-
nal TGF- 1 (exogenous) and without evidence of inflam-
mation, gestation day 18 TGF- 1 null T cells already ex-
hibit increased apoptosis. Thymocyte death due to
absence of inherent TGF- 1 is further amplified by anti-
CD3 both in vitro and in vivo, documenting that TGF-
 1 /  thymocytes are exquisitely sensitive to TCR-medi-
ated cell death.
The increased sensitivity to apoptosis appears also to be
an essential feature of TGF- 1 gene deleted–peripheral T
cells. Several unexpected findings emerged. First, although
both CD4  and CD8  T cells exhibit increased sensitivity
to apoptosis, the decrease in CD8  peripheral T cells is
more dramatic, leading to an abnormal skewing of the
CD4/CD8 ratio, irrespective of inflammation. While only
Fas-mediated apoptosis increased in CD4  T cells, TGF-
 1–null CD8  T cells are more sensitive to both Fas and
TNFR-mediated death signals, which may offer a clue for
the increased ratio of CD4 to CD8. Secondly, TGF- 1 / 
lymphocytes undergo spontaneous as well as TCR-medi-
ated apoptosis. The increased sensitivity to cell death of
TGF- 1 /  T cells cannot be attributed primarily to prior
activation and/or secondary cytokines, although some in-
fluence of these factors cannot be absolutely excluded.
Another surprising finding in the current study is that
anti-Fas antibody (Jo2) directly kills peripheral CD4  and
CD8  T cells of TGF- 1 /  mice within 16–24 h. It is
unusual for anti-Fas antibody to induce freshly isolated pe-
ripheral T cells to become apoptotic after only overnight
incubation, since normal T cells do not become susceptible
to cell death in response to Fas cross-linking until they have
Figure 8. Loss of   m in TGF- 1 /  T cells. (A) Spleen
cells from TGF- 1 /  (9 d old, n   2) (lower) or age-
matched TGF- 1 /  (n   2) (upper) mice were harvested
and pooled. Cells were assayed immediately (fresh) or cul-
tured with indicated reagents as in Fig. 4 A for 16 h. To
detect   m, cells were first stained with PE–anti-CD4 or
PE–anti-CD8 antibodies, washed, and resuspended in
complete DMEM containing 25 nM DiOC6 (Molecular
Probes) for 40 min at 37 C as described previously (refer-
ence 34). CD4  T cells were gated and the profiles of
DiOC6 on FL-1 versus CD4 on FL-2 are displayed.
DiOC6 staining in CD8  T cells (data not shown) was
similar to CD4  T cells except for a significant increase in
DiOC6
low cells after mTNF-  treatment. The experiment
was repeated three times with similar results. (B and C)
Electron micrograph of a fetal thymocyte from TGF- 1 / 
mouse as in Fig. 1 D (gestation day 18). Original magnifica-
tion: 16,000 . Abnormal mitochondria (Boxed, higher
magnification, original magnification: 25,000  in C) ap-
peared in TGF- 1 null T cells. Electron density in mito-
chondrial matrix was increased and cristae lost with dilated
intracristal space. M, mitochondria; N, nucleus.450 TGF- 1 Controls T Cell Apoptosis
been activated for extended periods of time (33, 51, 52).
TGF- 1 /  peripheral T cells express higher levels of death
receptors including Fas, which appears to be a phenotypic
characteristic, but not necessarily linked to inflammation.
Although the rapid cell death by anti-Fas antibody in these
null T cells may be attributed to the upregulation of Fas
and FasL, parallel cultures of wild-type T cells stimulated
with anti-CD3 antibody overnight to express equivalent
levels of Fas (33) do not succumb to anti-Fas–induced le-
thality (Fig. 4, B and C). Thus, it is unlikely that the super-
sensitivity to anti-Fas–induced apoptosis in TGF- 1 /  T
cells is merely due to their increased expression of death re-
ceptors. Since anti-Fas antibody specifically kills null pe-
ripheral naive (CD44 /low) T cells (Fig. 2 C) and neutraliz-
ing anti–TNF-  and IFN-  antibodies fail to prevent their
Fas-mediated death, the mechanism is likely independent
of cellular activation and/or cytokine release. Conse-
quently, the increased susceptibility to death receptor me-
diated–T cell death appears to be a characteristic of TGF-
 1 gene–deleted T cells.
On the basis of this novel observation that enhanced T
cell apoptosis is a fundamental characteristic of TGF- 1–
deleted T cells, one immediate question is how TGF- 1
normally regulates T cell apoptosis. One plausible explana-
tion would be that the lack of TGF- 1 production and re-
lease would mitigate TGF-  receptor–mediated signaling,
and previous studies have found that inclusion of exoge-
nous TGF-  in cell culture during the activation phase
protects normal T cells from AICD (24–26, 51). Although not
disputing that TGF- 1 receptor–mediated signaling con-
tributes to protection, this may represent only the tip of the
iceberg in a very complex picture. Previous studies adding
TGF-  to normal T cells or hybridoma cells have not ex-
cluded the possibility that endogenous T cell–derived
TGF-  might also play an important role, since TGF- 
upregulates its own production in both macrophages and T
cells (53, 54). In our study, exogenous TGF- 1 failed to
rescue or prevent spontaneous and death receptor–medi-
ated T cell apoptosis in TGF- 1 /  T cells, whereas these
null T cells express normal levels of TGF- 1 receptors.
Secondly, T cells deficient in Smad3, a key mediator in the
TGF- –receptor signaling cascade, have no significant
spontaneous or Fas-mediated–T cell death compared with
wild-type T cells, although these null T cells express an ef-
fector/memory phenotype (47). Thus, a pathway distinct
from the TGF- 1–TGF-  receptor-mediated signaling
cascade was considered in the dysregulated T cell death in
the TGF- 1 /  mice.
Mitochondria are considered the common effector of
cell death and TGF-  is located within the mitochondria
of T cells (Figs. 6 and 7), suggesting a connection in the
pathway to death. The data are consistent with the previ-
ous demonstration of TGF-  within the mitochondria in
both liver and heart cells (30) and favor a potential role for
TGF-  in maintaining   m. Indeed, deletion of the TGF-
 1 gene was associated with a loss of   m. In this regard,
the presence of TGF- 1 must normally promote the integ-
rity of   m to dissociate the death signals from the initia-
tion phase. The significant increase in disrupted     m
(DiOC6
low) in T cells in asymptomatic TGF- 1 /  mice
and particularly, the multiple forms of abnormal mitochon-
dria in the day 18 fetal thymuses strongly indicate an in-
herent defect of mitochondrial structure and function.
Whether TGF-  is involved in the process of ATP synthe-
sis is conceivable, but aberrant mitochondrial   m must
promote increased spontaneous apoptosis. The defect also
sensitizes to death signals derived from the selective or
“private” phase such as FasL–Fas receptors. Anti-Fas anti-
Figure 9. Prestimulation of TGF- 1 /  T cells with anti-CD3 plus
CD28 failed to upregulate Bcl–XL or to prevent subsequent T cell apop-
tosis induced by  -irradiation. (A) Bcl–XL mRNA expression in T cells.
Lymph node cells were stimulated with anti-CD3 and CD28 antibodies or
medium only overnight. RNA was extracted as described in the Methods
and Materials. Bcl–XL mRNA was assayed with RPA by using mAPO-2
set template. 5  g of RNA was loaded into each lane of gel. The cor-
rected ratio of mRNA of BcL–XL to GAPDH is shown. (B) Western blot
analysis of Bcl–XL in lymph node T cells. Expression of Bcl–XL was de-
tected with anti-Bcl–XL monoclonal antibody (BD PharMingen). 100  g
of protein was loaded into each lane. (C)  -irradiation induced T cell
apoptosis. Lymph node cells were prestimulated with anti-CD3 and CD28
antibodies (black bar) or medium only (white bar) overnight, washed, and
then irradiated. After 6 h, cells were stained with 7-AAD together with
surface PE-CD4 and FITC-CD8 antibodies. Cells were analyzed by
FACS®. CD4  or CD8  T cells were gated and the 7-AAD  (apoptotic/
dead) and 7-AAD  (live) on FL3 channel were calculated. Data shown are
percentages of 7-AAD  cells within the CD4  or CD8  T cells. The
shown data are a representative of two experiments.451 Chen et al.
body causes further reduction of   m and apoptosis.
Whether Fas-mediated null T cell   m disruption involves
caspase-1 (55) and/or other caspases remains to be deter-
mined. This finding may offer an intriguing clue as to why
anti-Fas antibody fails to induce apoptosis in TGF- 1 in-
tact normal T cells, despite the expression of Fas receptors
on the surface. Therefore, it is not difficult to conceive
why exogenous TGF- 1 fails to rescue both spontaneous
and death receptor-induced apoptosis, because it is unlikely
that exogenous TGF- 1–TGF-  receptor signaling could
restore the disrupted   m, a cornerstone that marks the
point of no return in a cell condemned to die (9–11, 34,
48). The possibility of protection by endogenous TGF- 1
induced by exogenous TGF- 1 is also absent in TGF- 1 / 
mice. Moreover, the fact that cyclosporin A, an agent
known to induce TGF-  in normal T cells (29, 56), inhib-
its loss of   m (57) strengthens the connection between
TGF-  and the integrity of   m..
The failure to upregulate the antiapoptotic protein Bcl–
XL after anti-CD3 plus CD28 challenge in TGF- 1 /  T
cells is fascinating, since Bcl–XL is located predominantly
in the outer mitochondrial membrane and its induction
prevents normal T cells from the subsequent programmed
cell death induced by  -irradiation (33) and by Fas-induced
apoptosis (49). On the one hand, it offers an explanation
for the failure of anti-CD3 plus CD28 prestimulation to
rescue the secondary irradiation-induced cell death in
TGF- 1 /  T cells. More importantly, this finding may
indicate a previously unrecognized link between TGF- 1,
mitochondrial proteins such as Bcl–XL and the control of
  m. How TGF- 1 regulates Bcl–XL expression remains
to be determined, but exacerbation of TGF- 1 /  T cell
apoptosis by anti-CD3 plus anti-CD28 or anti-Fas may be
the consequence of the inability to upregulate this Bcl–XL
protein to protect   m.
This protective mechanism of TGF- 1 in normal T
cells may involve prevention of the release of other death
factors such as apoptosis-inducing factor, cytochrome c,
and/or caspase-9 (10–12, 57), which in turn are responsi-
ble for the killing of the cells, and is under extensive inves-
tigation. Our preliminary data indicate that increased reac-
tive oxygen species and cytochrome c are found in the
cytoplasm of TGF- 1 /  T cells, which are downstream
of the loss of   m (data not shown). Whether these find-
ings are generalizable to nonlymphoid cells and involve
key regulatory elements such as nuclear factor  B (44)
and/or other Bcl-2 family protein-dependent sequelae
(21–23) remains to be pursued.
Finally, a paradox emerges from the fact that increased
apoptosis of TGF- 1 null T cells is accompanied with or
followed by massive inflammation and untimely death of all
TGF- 1 null mice (1, 2). Resolution of this paradox may
rely on a well-known fact that apoptosis and clearing of ap-
optotic cells are noninflammatory events, involving immu-
noregulatory cytokines such as TGF-  produced by macro-
phages during their phagocytosis of apoptotic cells (58) to
dampen inflammation. With increasing cell death and lack-
ing requisite TGF-  release during phagocytosis, the balance
of the immune response shifts toward the uncontrolled pro-
duction of proinflammatory cytokines such as TNF-  by
phagocytically activated macrophages (unpublished data).
The death of these null animals becomes unavoidable.
In summary, we have provided evidence for TGF- 1 as
a pivotal regulator in the control of the death of T cells.
While TGF-  may play a role at several levels, an underly-
ing mechanism may be the ability of TGF-  to maintain
the integrity of mitochondria by protecting   m. This
protective mechanism may occur independently of the
classic TGF- 1 receptor-mediated signaling pathway and
irrespective of inflammation. Our data also indicate that
TGF- 1 may serve as a moderator in the normal apoptosis
process, interfering between the death signaling selective or
private phase and the mitochondrial effector phase. None-
theless, our data offer new clues for defining T cell resis-
tance and susceptibility to death in immunologic diseases,
as exemplified in the TGF-  null mouse. Manipulation of
TGF- 1 and its stronghold on death may enable rescue
and/or deletion of appropriate target cells not only in au-
toimmune-like diseases, but also in tumors, and potentially,
HIV infection.
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